While Gilead Sciences posted a strong Q2 earnings print, GILD stock saw profit-taking. Here's why the red ink could be an ...

Kite, the Santa Monica, California-based cell therapy subsidiary of Gilead, has entered a definitive agreement to pay $350 ...

CVS is opting against covering a twice-yearly injectable HIV prevention drug, drawing criticism from advocates who are ...

In this article, we will take a detailed look at the Top 10 Trending Stocks to Watch Ahead of Nvidia Earnings.

CVS Health, one of the nation’s largest pharmacy benefit managers, has declined to cover Gilead’s newly FDA-approved HIV ...

Another cell therapy biotech has run out of steam, this time before ever reaching the clinic. | Another cell therapy biotech ...

At the International AIDS Society meeting this year, a young woman from South Africa spoke. She is the first Black woman from ...

Imdelltra is a first-in-class immunotherapy for the treatment of extensive-stage small cell lung cancer (ES-SCLC) marketed by Amgen Royalty ...

BeOne Medicines entered a deal worth up to $950 million with Royalty Pharma selling its rights to global sales royalties of ...

Fort Worth's oldest African American Baptist church, which was recently put on a list of Most Endangered Places in the city, ...

The Asia Police Station in southern Manchester hosted its annual non-residential summer camp from August 11–16, with more ...

Orman also has spotted some stock-market winners. On CNBC's "Fast Money" in late October 2023, she recommended Palantir Technologies (PLTR), Microsoft (MSFT), Amazon.com (AMZN), Shopify (SHOP) and ...